1
|
Mandoj C, Pizzuti L, Sergi D, Sperduti I, Mazzotta M, Di Lauro L, Amodio A, Carpano S, Di Benedetto A, Botti C, Ferranti F, Antenucci A, D'Alessandro MG, Marchetti P, Tomao S, Sanguineti G, Giordano A, Maugeri-Saccà M, Ciliberto G, Conti L, Vici P, Barba M. Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. J Transl Med 2018; 16:129. [PMID: 29769125 PMCID: PMC5956941 DOI: 10.1186/s12967-018-1511-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 05/08/2018] [Indexed: 11/22/2022] Open
Abstract
Background Cancer and coagulation activation are tightly related. The extent to which factors related to both these pathologic conditions concur to patient prognosis intensely animates the inherent research areas. The study herein presented aimed to the development of a tool for the assessment and stratification of risk of death and disease recurrence in early breast cancer. Methods Between 2008 and 2010, two hundreds thirty-five (N: 235) patients diagnosed with stage I–IIA breast cancer were included. Data on patient demographics and clinic-pathologic features were collected in course of face-to-face interviews or actively retrieved from clinical charts. Plasma levels of plasminogen activator inhibitor type 1 (PAI-1), fragment 1 + 2 (F1 + 2), thrombin antithrombin complex (TAT), factor VIII (FVIII), and D-dimer (DD) were measured at breast cancer diagnosis and prior to any therapeutic procedure, including breast surgery. The risk of death was computed in terms of overall survival (OS), which was the primary outcome. For a subset of patients (N = 62), disease free survival (DFS) was also assessed as a measure of risk of disease recurrence. Results Median follow up was 95 months (range 6–112 months). Mean age at diagnosis was 60.3 ± 13.4 years. Cancer cases were more commonly intraductal carcinomas (N: 204; 86.8%), pT1 (131; 55.7%), pN0 (141; 60%) and G2 (126; 53.6%). Elevated levels of PAI-1 (113; 48.1%) represented the most frequent coagulation abnormality, followed by higher levels of F1 + 2 (97; 41.3%), DD (63; 27.0%), TAT (34; 40%), and FVIII (29; 12.3%). In univariate models of OS, age, pT, DD, FVIII were prognostically relevant. In multivariate models of OS, age (p = 0.043), pT (p = 0.001), levels of DD (p = 0.029) and FVIII (p = 0.087) were confirmed. In the smaller subgroup of 62 patients, lymph node involvement, percent expression of estrogen receptors and levels of FVIII impacted DFS significantly. Conclusions We developed a risk assessment tool for OS including patient- and cancer-related features along with biomarkers of coagulation activation in a cohort of early BC patients. Further studies are warranted to validate our prognostic model in the early setting and eventually extend its application to risk evaluation in the advanced setting for breast and other cancers. Electronic supplementary material The online version of this article (10.1186/s12967-018-1511-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Chiara Mandoj
- Department of Clinical Pathology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Laura Pizzuti
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Domenico Sergi
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Isabella Sperduti
- Biostatistics Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Marco Mazzotta
- Medical Oncology Unit Policlinico Sant'Andrea, Via di Grottarossa 1035/1039, 00189, Rome, Italy
| | - Luigi Di Lauro
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Antonella Amodio
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Silvia Carpano
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Anna Di Benedetto
- Department of Pathology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Claudio Botti
- Department of Surgery, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Francesca Ferranti
- Radiology Department, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Anna Antenucci
- Department of Clinical Pathology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Maria Gabriella D'Alessandro
- Department of Clinical Pathology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Paolo Marchetti
- Medical Oncology Unit Policlinico Sant'Andrea, Via di Grottarossa 1035/1039, 00189, Rome, Italy
| | - Silverio Tomao
- Department of Medico-Surgical Sciences and Biotechnologies, University of Rome "Sapienza", Corso della Repubblica 79, 04100, Latina, Italy
| | - Giuseppe Sanguineti
- Department of Radiotherapy, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Antonio Giordano
- Sbarro Institute for Cancer Research and Molecular Medicine e del Center for Biotechnology, College of Science and Technology, Temple University, 1900 N, 12th Street, Philadelphia, PA, USA
| | - Marcello Maugeri-Saccà
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.,Scientific Direction, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Gennaro Ciliberto
- Scientific Direction, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Laura Conti
- Department of Clinical Pathology, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Patrizia Vici
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
| | - Maddalena Barba
- Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. .,Scientific Direction, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
| |
Collapse
|
2
|
Drusco A, Fadda P, Nigita G, Fassan M, Bottoni A, Gardiman MP, Sacchi D, Calore F, Carosi M, Antenucci A, Casini B, Kelani H, Pescarmona E, Di Leva G, Zanesi N, Berger MS, Croce CM. Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin. EBioMedicine 2018; 30:105-112. [PMID: 29643013 PMCID: PMC5952410 DOI: 10.1016/j.ebiom.2018.03.022] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2018] [Revised: 03/20/2018] [Accepted: 03/20/2018] [Indexed: 11/24/2022] Open
Abstract
The World Health Organization has recently introduced molecular prognostic-diagnostic biomarkers in the classification of Central Nervous System (CNS) tumors. In order to characterize subclasses of tumors that cannot find a precise location in the current classification, and, or cannot be tested because of scant material, it is important to find new molecular biomarkers in tissue and, or biological fluid samples. In this study, we identified serum microRNAs that could serve as biomarkers for the diagnosis and prognosis of patients with tumors of glial origin. We retrospectively analyzed microRNA expression in the serum extracellular vesicles of patients with tumors of glial origin. Extracellular vesicles RNA was analyzed by Nanostring. qRT-PCR confirmed 6 overexpressed microRNAs: hsa-miR-4443, hsa-miR-422a, hsa-miR-494-3p, hsa-miR-502-5p, hsa-miR-520f-3p, and hsa-miR-549a. Hsa-miR-4443 was the only microRNA that showed significant differences in most comparisons. In situ hybridization (ISH), confirmed that our signature was mostly expressed in cancer cells. Importantly, hsa-miR-549a and hsa-miR-502-5p expression predicted prognosis in patients with tumors of glial origin. Although more studies are needed, we demonstrated that serum vesicles microRNA profiles are promising diagnostic and prognostic molecular biomarkers that will find an actual application in the clinical practice of CNS tumors.
Collapse
Affiliation(s)
- Alessandra Drusco
- Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States.
| | - Paolo Fadda
- CCC - Genomics Shared Resource, The Ohio State University, Columbus, OH, United States
| | - Giovanni Nigita
- Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States
| | - Matteo Fassan
- Dept. of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, Italy
| | - Arianna Bottoni
- Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States
| | - Marina P Gardiman
- Dept. of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, Italy
| | - Diana Sacchi
- Dept. of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, Italy
| | - Federica Calore
- Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States
| | - Mariantonia Carosi
- Dept. of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Anna Antenucci
- Dept. of Clinical Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Beatrice Casini
- Dept. of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Hesham Kelani
- Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States
| | - Edoardo Pescarmona
- Dept. of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | | | - Nicola Zanesi
- Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States
| | - Mitchell S Berger
- Dept. of Neurological Surgery, University of California, San Francisco (UCSF), San Francisco, CA, USA
| | - Carlo M Croce
- Dept. of Cancer Biology and Genetics (CBG), The Ohio State University, Columbus, OH, United States.
| |
Collapse
|
3
|
Terrenato I, Sperati F, Musicco F, Pozzi AF, di Turi A, Caterino M, de Lutio di Castelguidone E, Setola SV, Bellomi M, Neumaier CE, Conti L, Cigliana G, Merola R, Antenucci A, Orlandi G, Giordano A, Barba M, Canitano S. Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial. J Cell Physiol 2017; 233:2572-2580. [PMID: 28777459 DOI: 10.1002/jcp.26132] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Accepted: 08/03/2017] [Indexed: 01/10/2023]
Abstract
To assess the safety profile of iso-osmolar contrast medium (CM) versus low osmolar CM in cancer patients with an estimated glomerular filtration rate (eGFR) >60 ml/min. In this multicenter, blind trial of patients seeking a chest-abdomen-pelvis contrast enhanced computed tomography (CT) with iodated CM, participants were centrally randomized to iodixanol or iopromide. Contrast induced nephropathy (CIN) at 24 and/or 72 hr were our primary outcomes. We further considered irreversible CIN, average eGFR percentage variation (%Δ), and adverse events (AEs). Overall, 607 patients were enrolled. Among them, 497 eligible patients were randomized to iodixanol (N: 247) or iopromide (N: 250). No differences emerged by descriptive characteristics. Seven and 3 CIN at 24 hr (p = 0.34) and 8 and 2 CIN at 72 hr (p = 0.11) occurred in the iopromide and iodixanol group, respectively. Within the subgroup of individual patients who developed CIN (N: 17), the event rate was higher in the iopromide arm (p = 0.045). No cases of permanent CIN or significant differences in terms of AEs or GFR %Δ were observed. Our results suggest a more favorable safety profile of iodixanol versus iopromide. Adequately sized trials with similar design are warranted to confirm our findings and clarify the underlying biological mechanisms.
Collapse
Affiliation(s)
- Irene Terrenato
- Biostatistic Unit, Regina Elena National Cancer Institute, Rome, Italy
| | - Francesca Sperati
- Biostatistic Unit, Regina Elena National Cancer Institute, Rome, Italy
| | - Felice Musicco
- Service of Pharmacovigilance, Regina Elena National Cancer Institute, Rome, Italy
| | | | - Annunziata di Turi
- Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy
| | - Mauro Caterino
- Department of Diagnostic Imaging, Regina Elena National Cancer Institute, Rome, Italy
| | | | - Sergio V Setola
- Department of Diagnostic Imaging, Radiant and Metabolic Therapy, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy
| | - Massimo Bellomi
- Department of Medical Imaging and Radiation Sciences, European Institute of Oncology, Milan, Italy.,Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy
| | - Carlo E Neumaier
- Diagnostic Imaging and Senology, IRCCS-A.O.U., San Martino-IST, Genoa, Italy
| | - Laura Conti
- Departement of Clinical Patology, Regina Elena National Cancer Institute, Rome, Italy
| | - Giovanni Cigliana
- Departement of Clinical Patology, Regina Elena National Cancer Institute, Rome, Italy
| | - Roberta Merola
- Departement of Clinical Patology, Regina Elena National Cancer Institute, Rome, Italy
| | - Anna Antenucci
- Departement of Clinical Patology, Regina Elena National Cancer Institute, Rome, Italy
| | - Giulia Orlandi
- Departement of Clinical Patology, Regina Elena National Cancer Institute, Rome, Italy
| | - Antonio Giordano
- Department of Medicine, Surgery and Neuroscience, University of Siena and Istituto Toscano Tumori (ITT), Siena, Italy.,Department of Biology, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, Pennsylvania
| | - Maddalena Barba
- Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy.,Division of Medical Oncology 2, Regina Elena National Cancer Institute, Rome, Italy
| | - Stefano Canitano
- Department of Diagnostic Imaging, Regina Elena National Cancer Institute, Rome, Italy
| |
Collapse
|
4
|
Farello G, Ferrara P, Antenucci A, Basti C, Verrotti A. The link between obesity and migraine in childhood: a systematic review. Ital J Pediatr 2017; 43:27. [PMID: 28270183 PMCID: PMC5341414 DOI: 10.1186/s13052-017-0344-1] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Accepted: 02/22/2017] [Indexed: 12/19/2022] Open
Abstract
Obesity and headache are two highly prevalent diseases both in adults and children and they are associated with a strong personal and social impact. Many studies suggest that obesity is comorbid with headache in general, and migraine in particular and obesity seems to be a risk factor for migraine progression and for migraine frequency both in adults and in children. Research shows that there are multiple areas of overlap between migraine pathophysiology and the central and peripheral pathways regulating feeding: inflammatory mediators such as the calcitonin gene-related protein (CGRP), neurotransmitters such as serotonin, peptides such as orexin and adipocytokines such as adiponectin (ADP) and leptin could explain the common pathogenesis. In this paper we discussed the association between obesity and migraine through the analysis of the most recent studies in children and we reviewed data from literature in order to assess the association between obesity and headache and to clarify the possible common pathogenic mechanisms.
Collapse
Affiliation(s)
- G Farello
- Department of Pediatrics, University of L'Aquila, Via Vetoio 1, Coppito, 67100, L'Aquila, Italy.
| | - P Ferrara
- Department of Pediatrics, Catholic University, A. Gemelli Hospital, Rome, Italy
| | - A Antenucci
- Department of Pediatrics, University of L'Aquila, Via Vetoio 1, Coppito, 67100, L'Aquila, Italy
| | - C Basti
- Department of Pediatrics, University of L'Aquila, Via Vetoio 1, Coppito, 67100, L'Aquila, Italy
| | - A Verrotti
- Department of Pediatrics, University of L'Aquila, Via Vetoio 1, Coppito, 67100, L'Aquila, Italy
| |
Collapse
|
5
|
Drusco A, Bottoni A, Laganà A, Acunzo M, Fassan M, Cascione L, Antenucci A, Kumchala P, Vicentini C, Gardiman MP, Alder H, Carosi MA, Ammirati M, Gherardi S, Luscrì M, Carapella C, Zanesi N, Croce CM. A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget 2016; 6:20829-39. [PMID: 26246487 PMCID: PMC4673232 DOI: 10.18632/oncotarget.4096] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2015] [Accepted: 05/14/2015] [Indexed: 12/12/2022] Open
Abstract
Central Nervous System malignancies often require stereotactic biopsy or biopsy for differential diagnosis, and for tumor staging and grading. Furthermore, stereotactic biopsy can be non-diagnostic or underestimate grading. Hence, there is a compelling need of new diagnostic biomarkers to avoid such invasive procedures. Several biological markers have been proposed, but they can only identify specific prognostic subtype of Central Nervous System tumors, and none of them has found a standardized clinical application.The aim of the study was to identify a Cerebro-Spinal Fluid microRNA signature that could differentiate among Central Nervous System malignancies.CSF total RNA of 34 neoplastic and of 14 non-diseased patients was processed by NanoString. Comparison among groups (Normal, Benign, Glioblastoma, Medulloblastoma, Metastasis and Lymphoma) lead to the identification of a microRNA profile that was further confirmed by RT-PCR and in situ hybridization.Hsa-miR-451, -711, 935, -223 and -125b were significantly differentially expressed among the above mentioned groups, allowing us to draw an hypothetical diagnostic chart for Central Nervous System malignancies.This is the first study to employ the NanoString technique for Cerebro-Spinal Fluid microRNA profiling. In this article, we demonstrated that Cerebro-Spinal Fluid microRNA profiling mirrors Central Nervous System physiologic or pathologic conditions. Although more cases need to be tested, we identified a diagnostic Cerebro-Spinal Fluid microRNA signature with good perspectives for future diagnostic clinical applications.
Collapse
Affiliation(s)
| | | | - Alessandro Laganà
- Dept. of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Mario Acunzo
- MVIMG, The Ohio State University, Columbus, OH, USA
| | - Matteo Fassan
- Dept. of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, Padua, Italy
| | - Luciano Cascione
- Lymphoma & Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland.,IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - Anna Antenucci
- UOSD of Clinical Pathology, Regina Elena Institute, Rome, Italy
| | | | - Caterina Vicentini
- ARC-NET Research Centre, University and Hospital Trust of Verona, Verona, Italy
| | - Marina P Gardiman
- Dept. of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padua, Padua, Italy
| | | | | | - Mario Ammirati
- Dept. of Neurological Surgery, The Ohio State University, OH, USA
| | | | - Marilena Luscrì
- Dept. of Anesthesiology, Sandro Pertini Hospital, Rome, Italy
| | | | | | | |
Collapse
|
6
|
Vici P, Pizzuti L, Di Lauro L, Conti L, Mandoj C, Antenucci A, Digiesi G, Sergi D, Amodio A, Marchetti P, Sperati F, Valle M, Garofalo A, Vizza E, Corrado G, Vincenzoni C, Tomao F, Kayal R, Marsella A, Carosi M, Antoniani B, Giordano A, Maugeri-Saccà M, Barba M. Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. J Cancer 2016; 7:516-22. [PMID: 26958087 PMCID: PMC4780127 DOI: 10.7150/jca.13578] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2015] [Accepted: 12/08/2015] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Over the last twenty years, the efforts of the scientific community devoted to the comprehension and treatment of ovarian cancer have remained poorly remunerative, with the case-fatality ratio of this disease remaining disappointedly high. Limited knowledge of the basic principles regulating ovarian carcinogenesis and factors impacting the course of disease may significantly impair our ability to intervene in early stages and lessen our expectations in terms of treatment outcomes. In the present study, we sought to assess whether metabolic factors and anthropometric indicators, i.e., pre-treatment fasting glucose and body mass index, are associated with renown cancer related prognostic factors such as tumour stage and grade at diagnosis. MATERIALS AND METHODS Study participants were 147 women diagnosed with epithelial ovarian cancer and treated with platinum based regimens and/or surgery at the Regina Elena National Cancer Institute of Rome, Italy. Glucose levels were assessed at the institutional laboratories on venous blood collected in overnight fasting conditions and prior to any therapeutic procedure. Stage was coded according to the FIGO staging system based on the results of the diagnostic workup, while tumour grade was locally assessed by an expert pathologist. Participants' characteristics were descriptively analyzed for the overall study population and in a subgroup of 70 patients for whom data on body mass index (BMI) were available. FIGO stage and grade were compared by categories of pre-treatment fasting glucose defined upon the median value, i.e., 89 mg/dl. The association of interest was tested in regression models including BMI. RESULTS For the overall study population, patients in the lowest category of fasting glucose were significantly more likely to exhibit a FIGO stage III-IV at diagnosis compared with their counterpart in the highest glucose category (81.3 vs 66.7%, p: 0.021). Subgroup analysis in 70 patients with BMI data confirmed this association (81.5 vs 55.8, p: 0.049), which remained significant when tested in regression models including BMI (OR: 0.28 95% CI 0.086-0.89, p: 0.031). No relevant evidence emerged when testing the association between fasting glucose and tumour grade. CONCLUSIONS In patients diagnosed with epithelial ovarian cancer, pre-treatment glucose levels appear to be inversely associated with FIGO stage. Further studies are warranted to eventually confirm and correctly interpret the implications of this novel finding.
Collapse
Affiliation(s)
- Patrizia Vici
- 1. Division of Medical Oncology 2, Regina Elena National Cancer Institute, Rome, Italy
| | - Laura Pizzuti
- 1. Division of Medical Oncology 2, Regina Elena National Cancer Institute, Rome, Italy
| | - Luigi Di Lauro
- 1. Division of Medical Oncology 2, Regina Elena National Cancer Institute, Rome, Italy
| | - Laura Conti
- 2. Division of Clinical Pathology, Regina Elena National Cancer Institute, Rome, Italy
| | - Chiara Mandoj
- 2. Division of Clinical Pathology, Regina Elena National Cancer Institute, Rome, Italy
| | - Anna Antenucci
- 2. Division of Clinical Pathology, Regina Elena National Cancer Institute, Rome, Italy
| | - Giovanna Digiesi
- 2. Division of Clinical Pathology, Regina Elena National Cancer Institute, Rome, Italy
| | - Domenico Sergi
- 1. Division of Medical Oncology 2, Regina Elena National Cancer Institute, Rome, Italy
| | - Antonella Amodio
- 1. Division of Medical Oncology 2, Regina Elena National Cancer Institute, Rome, Italy
| | - Paolo Marchetti
- 3. Oncology Unit, Sant'Andrea Hospital, La Sapienza University of Rome, Italy
| | - Francesca Sperati
- 4. Biostatistics Unit-Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy
| | - Mario Valle
- 5. General Surgery, Regina Elena National Institute, Rome, Italy
| | - Alfredo Garofalo
- 5. General Surgery, Regina Elena National Institute, Rome, Italy
| | - Enrico Vizza
- 6. Gynecological Oncology, Regina Elena National Cancer Institute, Rome, Italy
| | - Giacomo Corrado
- 6. Gynecological Oncology, Regina Elena National Cancer Institute, Rome, Italy
| | - Cristina Vincenzoni
- 6. Gynecological Oncology, Regina Elena National Cancer Institute, Rome, Italy
| | - Federica Tomao
- 7. Department of Gynecologic Oncology, University “Sapienza”, Viale del Policlinico 155, 00161 Rome, Italy
| | - Ramy Kayal
- 8. Department of Radiology, Regina Elena National Cancer Institute, Rome, Italy
| | - Annalise Marsella
- 8. Department of Radiology, Regina Elena National Cancer Institute, Rome, Italy
| | - Mariantonia Carosi
- 9. Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy
| | - Barbara Antoniani
- 9. Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy
| | - Antonio Giordano
- 10. Sbarro Institute for Cancer Research and Molecular Medicine e del Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA
- 11. Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - Marcello Maugeri-Saccà
- 1. Division of Medical Oncology 2, Regina Elena National Cancer Institute, Rome, Italy
- 12. Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy
| | - Maddalena Barba
- 1. Division of Medical Oncology 2, Regina Elena National Cancer Institute, Rome, Italy
- 12. Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy
| |
Collapse
|
7
|
Molica S, Digiesi G, D'Arena G, Mirabelli R, Antenucci A, Conti L, Gentile M, Musto P, Neri A, Morabito F. Serum levels of soluble calreticulin predict for time to first treatment in early chronic lymphocytic leukaemia. Br J Haematol 2016; 175:983-985. [PMID: 26728120 DOI: 10.1111/bjh.13907] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Stefano Molica
- Haematology-Oncology Department, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
| | | | - Giovanni D'Arena
- Haematology-Oncology Department, IRCCS Rionero in Vulture, Potenza, Italy
| | - Rosanna Mirabelli
- Haematology-Oncology Department, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
| | - Anna Antenucci
- Clinical Pathology Service, IRCCS Regina Elena, Roma, Italy
| | - Laura Conti
- Clinical Pathology Service, IRCCS Regina Elena, Roma, Italy
| | - Massimo Gentile
- Haematology-Oncology Department, Azienda Ospedaliera Cosenza, Cosenza, Italy
| | - Pellegrino Musto
- Haematology-Oncology Department, IRCCS Rionero in Vulture, Potenza, Italy
| | - Antonino Neri
- Research Centre for the Study of Leukaemia, Institute for Cancer Research and Treatment Foundation, University of Milan, Milan, Italy
| | - Fortunato Morabito
- Haematology-Oncology Department, Azienda Ospedaliera Cosenza, Cosenza, Italy
| |
Collapse
|
8
|
Barba M, Pizzuti L, Conti L, Mandoj C, Digiesi G, Antenucci A, Sergi D, Di Lauro L, Amodio A, Carpano S, Sperati F, Valle M, Garofalo A, Vizza E, Vincenzoni C, Corrado G, Maugeri-Saccà M, Vici P. The impact of fasting glucose on clinical-pathological features in epithelial ovarian cancer: results from a historic cohort. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv339.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Piludu F, Marzi S, Pace A, Villani V, Fabi A, Carapella CM, Terrenato I, Antenucci A, Vidiri A. Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas. Neuroradiology 2015; 57:1269-80. [PMID: 26364181 DOI: 10.1007/s00234-015-1582-9] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2015] [Accepted: 08/14/2015] [Indexed: 12/25/2022]
Abstract
INTRODUCTION The aim of this study is to investigate whether early changes in tumor volume and perfusion measurements derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may predict response to antiangiogenic therapy in recurrent high-grade gliomas. METHODS Twenty-seven patients who received bevacizumab every 3 weeks were enrolled in the study. For each patient, three MRI scans were performed: at baseline, after the first dose, and after the fourth dose of bevacizumab. The entire tumor volume (V(tot)), as well as contrast-enhanced and noncontrast-enhanced tumor subvolumes (V(CE-T1) and V(NON-CE-T1), respectively) were outlined using post-contrast T1-weighted images as a guide for the tumor location. Histogram analysis of normalized IAUGC (nIAUGC) and transfer constant K(trans) maps were performed. Each patient was classified as a responder patient if he/she had a partial response or a stable disease or as a nonresponder patient if he/she had progressive disease. RESULTS Responding patients showed a larger reduction in V(NON-CE-T1) after a single dose, compared to nonresponding patients. Tumor subvolumes with increased values of nIAUGC and K(trans), after a single dose, significantly differed between responders and nonresponders. The radiological response was found to be significantly associated to the clinical outcome. After a single dose, V(tot) was predictive of overall survival (OS), while V(CE-T1) showed a tendency of correlation with OS. CONCLUSION Tumor subvolumes with increased nIAUGC and K(trans) showed the potential for improving the diagnostic accuracy of DCE. Early assessments of the entire tumor volume, including necrotic areas, may provide complementary information of tumor behavior in response to anti-VEGF therapies and is worth further investigation.
Collapse
Affiliation(s)
- Francesca Piludu
- Radiology and Diagnostic Imaging Department, Regina Elena National Cancer Institute, Rome, Italy
| | - Simona Marzi
- Medical Physics Laboratory, Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome, 00144, Italy.
| | - Andrea Pace
- Neurology Division, Regina Elena National Cancer Institute, Rome, Italy
| | - Veronica Villani
- Neurology Division, Regina Elena National Cancer Institute, Rome, Italy
| | - Alessandra Fabi
- Oncology Department, Regina Elena National Cancer Institute, Rome, Italy
| | | | - Irene Terrenato
- Biostatistics-Scientific Direction, Regina Elena National Cancer Institute, Rome, Italy
| | - Anna Antenucci
- Clinical Pathology, Regina Elena National Cancer Institute, Rome, Italy
| | - Antonello Vidiri
- Radiology and Diagnostic Imaging Department, Regina Elena National Cancer Institute, Rome, Italy
| |
Collapse
|
10
|
Merola R, Tomao L, Antenucci A, Sperduti I, Sentinelli S, Masi S, Mandoj C, Orlandi G, Papalia R, Guaglianone S, Costantini M, Cusumano G, Cigliana G, Ascenzi P, Gallucci M, Conti L. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. J Exp Clin Cancer Res 2015; 34:15. [PMID: 25651917 PMCID: PMC4324853 DOI: 10.1186/s13046-015-0127-8] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Accepted: 01/20/2015] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Prostate cancer (PCa) is the most common male cancer in Europe and the US. The early diagnosis relies on prostate specific antigen (PSA) serum test, even if it showed clear limits. Among the new tests currently under study, one of the most promising is the prostate cancer gene 3 (PCA3), a non-coding mRNA whose level increases up to 100 times in PCa tissues when compared to normal tissues. With the present study we contribute to the validation of the clinical utility of the PCA3 test and to the evaluation of its prognostic potential. METHODS 407 Italian men, with two or more PCa risk factors and at least a previous negative biopsy, entering the Urology Unit of Regina Elena National Cancer Institute, were tested for PCA3, total PSA (tPSA) and free PSA (fPSA and f/tPSA) tests. Out of the 407 men enrolled, 195 were positive for PCa and 114 of them received an accurate staging with evaluation of the Gleason score (Gs). Then, the PCA3 score was correlated to biopsy outcome, and the diagnostic and prognostic utility were evaluated. RESULTS Out of the 407 biopsies performed after the PCA3 test, 195 (48%) resulted positive for PCa; the PCA3 score was significantly higher in this population (p < 0.0001) differently to tPSA (p = 0.87). Moreover, the PCA3 test outperformed the f/tPSA (p = 0.01). The sensitivity (94.9) and specificity (60.1) of the PCA3 test showed a better balance for a threshold of 35 when compared to 20, even if the best result was achieved considering a cutoff of 51, with sensitivity and specificity of 82.1% and 79.3%, respectively. Finally, comparing values of the PCA3 test between two subgroups with increasing Gs (Gs ≤ 6 versus Gs ≥ 7) a significant association between PCA3 score and Gs was found (p = 0.02). CONCLUSIONS The PCA3 test showed the best diagnostic performance when compared to tPSA and f/tPSA, facilitating the selection of high-risk patients that may benefit from the execution of a saturation prostatic biopsy. Moreover, the PCA3 test showed a prognostic value, as higher PCA3 score values are associated to a greater tumor aggressiveness.
Collapse
Affiliation(s)
- Roberta Merola
- Clinical Pathology, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
| | - Luigi Tomao
- Clinical Pathology, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
- Department of Sciences, University Roma Tre, Rome, Italy.
| | - Anna Antenucci
- Clinical Pathology, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
| | - Isabella Sperduti
- Scientific Direction, Regina Elena National Cancer Institute, IRCCS, Rome, Italy.
| | - Steno Sentinelli
- Department of Pathology, Regina Elena National Cancer Institute, IRCCS, Rome, Italy.
| | - Serena Masi
- Clinical Pathology, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
| | - Chiara Mandoj
- Clinical Pathology, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
| | - Giulia Orlandi
- Clinical Pathology, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
| | - Rocco Papalia
- Urology Department, Regina Elena National Cancer Institute, IRCCS, Rome, Italy.
| | | | - Manuela Costantini
- Urology Department, Regina Elena National Cancer Institute, IRCCS, Rome, Italy.
| | - Giuseppe Cusumano
- Urology Department, Regina Elena National Cancer Institute, IRCCS, Rome, Italy.
| | - Giovanni Cigliana
- Clinical Pathology, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
| | - Paolo Ascenzi
- Department of Sciences, University Roma Tre, Rome, Italy.
- Interdepartmental Laboratory of Electron Microscopy, University Roma Tre, Rome, Italy.
| | - Michele Gallucci
- Urology Department, Regina Elena National Cancer Institute, IRCCS, Rome, Italy.
| | - Laura Conti
- Clinical Pathology, Regina Elena National Cancer Institute, IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.
| |
Collapse
|
11
|
Pace A, Antenucci A, Mandoj C, Villani V, Carapella CM, Fabi A, Conti L. P17.64 * ANGIOGENIC AND PROCOAGULANT FACTORS IN PLASMA OF BRAIN TUMOUR PATIENTS TREATED WITH BEVACIZUMAB. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Vidiri A, Marzi S, Piludu F, Villani V, Antenucci A, Terrenato I, Fabi A, Pace A, Carapella CM. P16.06 * EARLY PERFUSION CHANGES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS TREATED WITH BEVACIZUMAB: PRELIMINARY EVALUATION BY THE PARAMETRIC RESPONSE MAP DERIVED FROM DYNAMIC CONTRAST-ENHANCED MRI. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
13
|
Sofra M, Antenucci A, Gallucci M, Mandoj C, Papalia R, Claroni C, Monteferrante I, Torregiani G, Gianaroli V, Sperduti I, Tomao L, Forastiere E. Perioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques. J Exp Clin Cancer Res 2014; 33:63. [PMID: 25129475 PMCID: PMC4431486 DOI: 10.1186/s13046-014-0063-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/04/2014] [Accepted: 07/15/2014] [Indexed: 12/26/2022]
Abstract
BACKGROUND Laparoscopic prostatectomy (LRP) may activate clotting system influencing the risk of perioperative thrombosis in patients with prostate cancer. Moreover, different anaesthetic techniques can also modify coagulant factors. Thus, the aim of this study was to investigate the effects on pro- and anti-coagulant and fibrinolytic factors of two established types of anaesthesia in patients with prostate cancer undergoing elective LRP. METHODS 102 patients with primary prostate cancer, who underwent conventional LRP or robot-assisted laparoscopic prostatectomy (RALP), were studied and divided into 2 groups to receive total intravenous anesthesia with target-controlled infusion (TIVA-TCI) or balanced inhalation anaesthesia (BAL) prior to surgery. Before the induction of anaesthesia (T0), 1 hr (T1) and 24 hrs post-surgery (T2), some pro-coagulant factors, fibronolysis markers, p-selectin and haemostatic system inhibitors were evaluated. RESULTS Both TIVA-TCI and BAL patients showed a marked and significant increase in pro-coagulant factors and consequent reduction in haemostatic system inhibitors in the early post operative period (p ≤ 0.004 for each markers). Use of RALP showed a significant increase in prothrombotic markers as compared to LRP. In TIVA patients undergoing LRP, a significant reduction of p-selectin levels between T0 and T2 (p = 0.001) was observed as compared to BAL, suggesting a better protective effect on platelet activation of anaesthetic agents used for TIVA. CONCLUSIONS Both anaesthetic techniques significantly seem to increase the risk of thrombosis in prostate cancer patients undergoing LRP, mainly when the robotic device was utilized, encouraging the use of a peri-operative thromboembolic prophylaxis in these patients.
Collapse
Affiliation(s)
- Maria Sofra
- Department of Anaesthesiology, Regina Elena, Roma National Cancer Institute, Via Elio Chianesi 53, Roma, 00144, Italy.
| | - Anna Antenucci
- Clinical Pathology, Regina Elena, Roma National Cancer Institute, Rome, Italy.
| | - Michele Gallucci
- Department of Urology, Regina Elena, Roma National Cancer Institute, Rome, Italy.
| | - Chiara Mandoj
- Clinical Pathology, Regina Elena, Roma National Cancer Institute, Rome, Italy.
| | - Rocco Papalia
- Department of Urology, Regina Elena, Roma National Cancer Institute, Rome, Italy.
| | - Claudia Claroni
- Department of Anaesthesiology, Regina Elena, Roma National Cancer Institute, Via Elio Chianesi 53, Roma, 00144, Italy.
| | - Ilaria Monteferrante
- Department of Anaesthesiology, Regina Elena, Roma National Cancer Institute, Via Elio Chianesi 53, Roma, 00144, Italy.
| | - Giulia Torregiani
- Department of Anaesthesiology, Regina Elena, Roma National Cancer Institute, Via Elio Chianesi 53, Roma, 00144, Italy.
| | - Valeria Gianaroli
- Department of Anaesthesiology, Regina Elena, Roma National Cancer Institute, Via Elio Chianesi 53, Roma, 00144, Italy.
| | - Isabella Sperduti
- Division of Biostatistic, Regina Elena, Roma National Cancer Institute, Rome, Italy.
| | - Luigi Tomao
- Clinical Pathology, Regina Elena, Roma National Cancer Institute, Rome, Italy.
| | - Ester Forastiere
- Department of Anaesthesiology, Regina Elena, Roma National Cancer Institute, Via Elio Chianesi 53, Roma, 00144, Italy.
| |
Collapse
|
14
|
Drusco A, Nuovo GJ, Zanesi N, Di Leva G, Pichiorri F, Volinia S, Fernandez C, Antenucci A, Costinean S, Bottoni A, Rosito IA, Liu CG, Burch A, Acunzo M, Pekarsky Y, Alder H, Ciardi A, Croce CM. MicroRNA profiles discriminate among colon cancer metastasis. PLoS One 2014; 9:e96670. [PMID: 24921248 PMCID: PMC4055753 DOI: 10.1371/journal.pone.0096670] [Citation(s) in RCA: 91] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2014] [Accepted: 04/10/2014] [Indexed: 12/11/2022] Open
Abstract
MicroRNAs are being exploited for diagnosis, prognosis and monitoring of cancer and other diseases. Their high tissue specificity and critical role in oncogenesis provide new biomarkers for the diagnosis and classification of cancer as well as predicting patients' outcomes. MicroRNAs signatures have been identified for many human tumors, including colorectal cancer (CRC). In most cases, metastatic disease is difficult to predict and to prevent with adequate therapies. The aim of our study was to identify a microRNA signature for metastatic CRC that could predict and differentiate metastatic target organ localization. Normal and cancer tissues of three different groups of CRC patients were analyzed. RNA microarray and TaqMan Array analysis were performed on 66 Italian patients with or without lymph nodes and/or liver recurrences. Data obtained with the two assays were analyzed separately and then intersected to identify a primary CRC metastatic signature. Five differentially expressed microRNAs (hsa-miR-21, -103, -93, -31 and -566) were validated by qRT-PCR on a second group of 16 American metastatic patients. In situ hybridization was performed on the 16 American patients as well as on three distinct commercial tissues microarray (TMA) containing normal adjacent colon, the primary adenocarcinoma, normal and metastatic lymph nodes and liver. Hsa-miRNA-21, -93, and -103 upregulation together with hsa-miR-566 downregulation defined the CRC metastatic signature, while in situ hybridization data identified a lymphonodal invasion profile. We provided the first microRNAs signature that could discriminate between colorectal recurrences to lymph nodes and liver and between colorectal liver metastasis and primary hepatic tumor.
Collapse
Affiliation(s)
- Alessandra Drusco
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
| | - Gerard J. Nuovo
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
| | - Nicola Zanesi
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
| | - Gianpiero Di Leva
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
| | - Flavia Pichiorri
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
| | - Stefano Volinia
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
- Dept. of Morphology, Surgery and Experimental Medicine, Universita' degli Studi, Ferrara, Italy
| | - Cecilia Fernandez
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
| | - Anna Antenucci
- UOSD of Clinical Pathology, Regina Elena Institute, Rome, Italy
| | - Stefan Costinean
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
| | - Arianna Bottoni
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
| | | | - Chang-Gong Liu
- Dept. Experimental therapeutic-unit 1950, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States of America
| | - Aaron Burch
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
| | - Mario Acunzo
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
| | - Yuri Pekarsky
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
| | - Hansjuerg Alder
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
| | - Antonio Ciardi
- Dep. of Radiologic and Oncologic Sciences and Pathology, University of Rome “La Sapienza”, Rome, Italy
| | - Carlo M. Croce
- MVIMG, Ohio State University, Columbus, Ohio, United States of America
- * E-mail:
| |
Collapse
|
15
|
Pace A, Antenucci A, Mandoj C, Villani V, Carapella CM, Fabi A, Conti L. Angiogenic and procoagulant factors in plasma of brain tumor patients treated with bevacizumab. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.2085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Andrea Pace
- Neurology, Regina Elena National Cancer Institute, Rome, Italy
| | - Anna Antenucci
- Clinical Pathology, Regina Elena Cancer Institute, Rome, Italy
| | - Chiara Mandoj
- Clinical Pathology, Regina Elena Cancer Institute, Rome, Italy
| | | | | | - Alessandra Fabi
- Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
| | - Laura Conti
- Clinical Pathology Service, Regina Elena National Cancer Institute, Rome, Italy
| |
Collapse
|
16
|
Acunzo M, Nuovo JG, Zanesi N, Di Leva G, Pichiorri F, Volinia S, Fernandez C, Costinenan S, Bottoni A, Burch A, Alder H, Conti L, Antenucci A, Rosito IA, Ciardi A, Liu CG, Drusco A, Croce CM. Abstract 5326: MicroRNA profiles discriminate among colon cancer metastasis. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-5326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
MicroRNAs are being exploited for diagnosis, prognosis and monitoring of cancer and other diseases. Their small non immunogenic size, high tissue specificity, and critical role in oncogenesis provide new biomarkers for diagnosing and classifying cancer as well as predicting patients’ outcomes. MicroRNAs signatures have been identified for many human tumors, including colorectal cancer. This tumor affects about one million individuals in developed countries, and about half of them die for recurrences. In most cases, metastatic disease is difficult to predict and to prevent with adequate therapies. The identification of microRNAs signatures for metastatic disease, could aid to define the risk and localization of recurrences in patients with unknown micrometastasis.
In this study, tissues of three different groups of colorectal cancer (CRC) patients were analyzed: microarray and cards analysis were performed on 66 patients with or without lymph nodes and/or liver recurrences; a second group of 16 metastatic patients were selected for RT-PCR; finally, in situ hybridization was carried out on tissue cores arrays belonging to a different set of patients with and without positive lymph nodes and/or liver metastasis.
MicroRNA-31, 21, 93, and 103 up-regulation together with miR-566 down-regulation defined the CRC metastatic signature. Moreover, in situ hybridization data defined metastatic localization: miR-200c up-regulation together with miR-566 down-regulation characterized lynphonodal invasion, while liver recurrences were defined by miR-31, 93 and 103 over-expression.
Citation Format: Mario Acunzo, Jerry G. Nuovo, Nicola Zanesi, Giampiero Di Leva, Flavia Pichiorri, Stefano Volinia, Cecilia Fernandez, Stefan Costinenan, Arianna Bottoni, Aaron Burch, Hansjuerg Alder, Laura Conti, Anna Antenucci, Immacolata A. Rosito, Antonio Ciardi, Chang G. Liu, Alessandra Drusco, Carlo M. Croce. MicroRNA profiles discriminate among colon cancer metastasis. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5326. doi:10.1158/1538-7445.AM2013-5326
Collapse
|
17
|
Schiavetti A, McDowell HP, Conti L, Altavista P, Antenucci A, Pizer B, Dominici C. Vascular endothelial growth factor serum levels in children with newly diagnosed rhabdomyosarcoma. Pediatr Blood Cancer 2012; 59:627-30. [PMID: 22231858 DOI: 10.1002/pbc.24072] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/12/2011] [Accepted: 12/13/2011] [Indexed: 11/06/2022]
Abstract
BACKGROUND The adverse prognostic impact of elevated levels of circulating Vascular Endothelial Growth Factor (VEGF) is described in several malignancies. However, no information is available in childhood rhabdomyosarcoma (RMS). In the present study, serum VEGF-A (sVEGF-A) was measured at diagnosis in a series of patients with RMS. PROCEDURE sVEGF-A was assessed retrospectively in 17 newly diagnosed RMS patients. sVEGF-A concentrations were determined by quantitative enzyme-linked immunoabsorbent ELISA kit and their possible associations with age at diagnosis, gender, histology, primary site, primary size, Intergroup Rhabdomyosarcoma Study (IRS) post-surgical group, and outcome were investigated. RESULTS sVEGF-A median value in patients with RMS was significantly higher than in controls: 499.0 pg/ml, range: 2,648.0 versus 301.5 pg/ml, range: 716.0 (P = 0.013). Although not statistically significant probably due to the limited number of patients, sVEGF-A median levels resulted higher in unfavorable primary sites (277.0 vs. 539.0 pg/ml; P = 0.31), and advanced groups (390.0 vs. 715.0; P = 0.29). Patients with shorter 5-year overall survival (OS) and 5-year progression-free survival (PFS) times also had higher sVEGF-A levels, although again the difference was not statistically significant (P = 0.18 and P = 0.22, respectively). CONCLUSIONS Circulating VEGF is significantly increased in pediatric patients with newly diagnosed RMS. Further studies in larger series of RMS patients are needed to understand whether measurements of circulating VEGF might have a role in assessing prognosis and modulating treatment.
Collapse
|
18
|
Schiavetti A, Ingrosso A, Antenucci A, Federici T, Megaro G, De Luca L, Conti L. Circulating vascular endothelial growth factor in childhood solid tumors: plasma and serum measurements. Anticancer Res 2012; 32:3565-3569. [PMID: 22843947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
BACKGROUND Serum and plasma vascular endothelial growth factor (VEGF) were measured in children with a solid tumor to investigate which provides better prognostic information. PATIENTS AND METHODS Seventeen patients under treatment were divided into two groups: without (n 8) and with (n 9) detectable disease at radiological assessment (groups I and II). The control group consisted of 26 healthy children. VEGF was tested by enzyme-linked ELISA kit. RESULTS Serum VEGF concentrations in group II were statistically higher than those in group I (p<0.05) and those in controls (p=0.001), whereas the difference between group I and controls was not statistically significant (p=0.067). Plasma VEGF concentrations in group II were also statistically higher than those in group I (p<0.01) and those in controls (p=0.0001); the difference between group I and controls was also statistically significant (p=0.004). CONCLUSION Plasma would be the more useful specimen for measurement of circulating VEGF in cancer childhood.
Collapse
|
19
|
Molica S, Digiesi G, Antenucci A, Levato L, Mirabelli R, Molica M, Gentile M, Giannarelli D, Sperduti I, Morabito F, Conti L. Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL). Leuk Res 2011; 36:443-7. [PMID: 22047708 DOI: 10.1016/j.leukres.2011.10.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2011] [Revised: 09/01/2011] [Accepted: 10/07/2011] [Indexed: 12/29/2022]
Abstract
Although vitamin D insufficiency is related to inferior prognosis in some cancers, limited data exist in hematologic malignancies. We evaluated the relationship between 25(OH)D serum levels and time to first treatment (TFT), a disease-specific end point, in 130 previously untreated Binet stage A chronic lymphocytic leukemia (CLL) patients. Measurement of 25(OH)D was performed by means of a direct, competitive chemiluminescence immunoassay using the DiaSorin LIAISON 25(OH)D TOTAL assay (DiaSorin, Inc., Stillwater, Minnesota). Overall, 41 patients (31.5%) had severe vitamin D insufficiency (<10 ng/mL), 66 (50.7%) had mild to moderate insufficiency (10-24 ng/mL), and 23 (17.6%) had 25(OH)D levels within the optimal range (25-80 ng/mL), with no relationship with between the season of sample collection and 25(OH)D level (P=0.188). A patient stratification according to these 3 groups led to significant difference in terms of TFT, with vitamin D insufficient patients having the shortest TFT (P=0.02). With respect to continuous 25(OH)D levels and clinical outcome, TFT was shorter as 25(OH)D decreased until a value of 13.5 ng/mL at which point the association of 25(OH)D and TFT remained constant. As a matter of fact, the 25(OH)D value of 13.5 ng/mL identified two patients subsets with different TFT risk (HR=1.91; 95% CI=1.06-3.44; P=0.03). In multivariate analysis the variable entering the model at a significant level were mutational status of IgVH (P<0.0001), serum thymidine kinase (P=0.02) and absolute lymphocyte count (P=0.03). Thus confirming the Mayo clinic experience, our data provide further evidence that 25(OH)D levels may be an important host factor influencing TFT of Binet stage A patients. Whether normalizing vitamin D levels may delay disease-progression of patients with early disease will require testing in future trials.
Collapse
Affiliation(s)
- Stefano Molica
- Dipartimento di Emato-oncologia, Azienda Ospedaliera di Catanzaro, Catanzaro, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Felici A, Naso G, Di Segni S, Vici P, Antenucci A, Angelini F, Pizzuti L, Mandoj C, D'Auria G, Fabi A, Tata A, Cognetti F, Papaldo P. Fulvestrant administered in two different schedules: Pharmacokinetics, biological markers, and activity. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Molica S, Digiesi G, Battaglia C, Cutrona G, Antenucci A, Molica M, Giannarelli D, Sperduti I, Gentile M, Morabito F, Ferrarini M. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. Eur J Haematol 2010; 85:314-20. [PMID: 20546021 DOI: 10.1111/j.1600-0609.2010.01482.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
We analyzed the correlation between well-established biological parameters of prognostic relevance in B-cell chronic lymphocytic leukemia (CLL) [i.e. mutational status of the immunoglobulin heavy chain variable region (IgVH), ZAP-70 and CD38 expression] and serum levels of B cell-activating factor (BAFF of the TNF family) by evaluating the impact of these variables on the time to first treatment (TFT) in a series of 169 previously untreated CLL patients in Binet stage A. Higher levels of BAFF were more frequently associated with female gender (P=0.02), younger age (P=0.01), Rai stage 0 (P=0.002), higher platelet count (P=0.005), mutated IgVH disease (P=0.002), higher occurrence of normal cytogenetic profile or presence of 13q deletion (P=0.02), low ZAP-70- (P=0.003), and CD38-expression (P=0.02). Maximally selected log-rank statistic plot identified a serum BAFF concentration of 0.313 ng/mL as the best cut-off (P<0.0001). This threshold recognized two subsets of patients with different TFT (P<0.0001). Because in multivariate analysis soluble BAFF [Hazard ratio (HR), 8.23; confidence Interval (CI) 95%,3.0-22.6, P<0.0001] and mutational status of IgVH (HR=2.60; CI 95% 1.10-6.14, P=0.03) maintained the discriminating power their combined effect on clinical outcome was assessed. When three groups were considered: (1) low-risk (n=93), patients with concordant IgVH(mut) and higher soluble BAFF; (2) intermediate-risk (n=50), patients with IgVH(mut) and low BAFF levels or IgVH(unmut) and soluble higher BAFF;(3) high-risk (n=26), patients with concordant IgVH (unmut) and low soluble BAFF, the 2-yr TFTs were, respectively, 95%, 85%, and 41% (P<0.0001). In conclusion, our results indicate that in early B-cell CLL, the biological profile including among other parameters soluble BAFF may provide a useful insight into the complex interrelationship of prognostic variables.
Collapse
Affiliation(s)
- Stefano Molica
- Medical Oncology Unit, Hematology-Oncology Department, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Matteucci C, Sorrentino R, Ettorre GM, Bellis L, Antenucci A, Beneduce L, Santoro R, Vennarecci G, Zuin J, Biasiolo A, Pontisso P, Pierimarchi P, Puoti C, Rasi G. Circulating Survivin-IGM is a Novel Candidate Biomarker of Cirrhosis and Increases with Child Score in Patients Affected by Liver Diseases. Int J Biol Markers 2009. [DOI: 10.1177/172460080902400336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background Survivin, also known as BIRC5, is the smallest member of the mammalian IAP family and is a well recognized inhibitor of apoptosis with an important role in cell-cycle regulation. It is detected in fetal and neoplastic adult tissue, but not in normal tissues. Survivin acts on cancer promotion not only by the inhibition of apoptosis but also by acceleration of the proliferative activity of cancer cells and several papers have suggested the involvement of this protein in hepatocarcino-genesis. It has been reported that the detection of HCC biomarkers circulating as IgM immune complexes (ICs) improved the diagnosis and prognosis of HCC. The aim of this study was to compare the expression of survivin as an IgM immune complex in serum from healthy controls and of patients with cirrhosis and patients with HCC to identify a novel biomarker for the monitoring of liver diseases. Methods Serum levels of survivin-IgM from 1 97 individuals, including 39 healthy subjects, 94 patients with cirrhosis and 64 with HCC, were measured by ELISA and the relationship with clinical parameters was evaluated. Results Survivin-IgM was almost undetectable in sera from healthy subjects, high in patients with cirrhosis, and moderately lower in patients with HCC. The survivin-IgM assay was positive in 62 of 94 patients with cirrhosis (66%) and in 28 of 64 patients with HCC (43.7%) using a cut-off of 264.89 AU/mL (specificity of 94%). Statistical analysis showed that IC values were significantly different between groups (cirrhosis versus healthy control group, p<0.001; HCC versus cirrhosis group, p<0.001). Circulating survivin-IgM ICs in patients with HCC were lower than in patients with cirrhosis; in fact, the statistical significance in comparison with healthy subjects was lost. On the other hand, the concentration of circulating survivin-IgM ICs was found to increase with progression of Child score. Conclusions The high expression of survivin-IgM in sera from patients with cirrhosis and the values of sensitivity indicate that survivin-IgM could be a novel candidate biomarker for cirrhotic disease. Furthermore, the increase in ICs with the progression of Child score seems to promote the survivin-IgM immune complex as marker of liver failure. Survivin-IgM was found to be lower in sera from HCC patients. Follow-up studies are in progress to monitor patients with cirrhosis and to validate the association of the downregulation of this marker with progression towards hepatocellular carcinoma.
Collapse
Affiliation(s)
- Claudia Matteucci
- Institute of neurobiology and Molecular Medicine - ARTOV, CNR, Rome
- Department of Experimental Medicine and Biochemical Science, University of Rome “Tor Vergata”, Rome
| | - Roberta Sorrentino
- Institute of neurobiology and Molecular Medicine - ARTOV, CNR, Rome
- Department of Experimental Medicine and Biochemical Science, University of Rome “Tor Vergata”, Rome
| | | | - Lia Bellis
- Department of Internal Medicine and Liver Unit, Marino general Hospital, Marino, Rome
| | | | | | - Roberto Santoro
- Division of general Surgery and Transplantation, San Camillo Hospital, Rome
| | | | | | - Alessandra Biasiolo
- Department of Clinical and Experimental Medicine, University of Padua, Padua - Italy
| | - Patrizia Pontisso
- Department of Clinical and Experimental Medicine, University of Padua, Padua - Italy
| | | | - Claudio Puoti
- Department of Internal Medicine and Liver Unit, Marino general Hospital, Marino, Rome
| | - Guido Rasi
- Institute of neurobiology and Molecular Medicine - ARTOV, CNR, Rome
| |
Collapse
|
23
|
Molica S, Digiesi G, Mirabelli R, Cutrona G, Antenucci A, Molica M, Giannarelli D, Sperduti I, Morabito F, Neri A, Baldini L, Ferrarini M. Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia. Eur J Haematol 2009; 83:208-14. [PMID: 19459926 DOI: 10.1111/j.1600-0609.2009.01273.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
We analyzed the correlation between well-established biological parameters of prognostic relevance in B-cell chronic lymphocytic leukemia (CLL) [i.e. mutational status of the immunoglobulin heavy chain variable region (IgV(H)), ZAP-70- and CD38-expression] and serum levels of CD26 (dipeptidyl peptidase IV, DPP IV) by evaluating the impact of these variables on the time to first treatment (TFT) in a series of 69 previously untreated Binet stage A B-cell CLL patients. By using a commercial ELISA we found that with exception of a borderline significance for ZAP-70 (P = 0.07) and CD38 (P = 0.08), circulating levels of CD26 did not correlate with either Rai substages (P = 0.520) or other biomarker [beta2-microglobulin (P = 0.933), LDH (P = 0.101), mutational status of IgV(H) (P = 0.320)]. Maximally selected log-rank statistic plots identified a CD26 serum concentration of 371 ng/mL as the best cut-off. This threshold allowed the identification of two subsets of patients with CD26 serum levels higher and lower that 371 ng/mL respectively, whose clinical outcome was different with respect to TFT (i.e. 46% and 71% at 5 yr respectively; P = 0.005). Along with higher serum levels of CD26, the univariate Cox proportional hazard model identified absence of mutation in IgV(H) (P < 0.0001) as predictor of shorter TFT. As in multivariate analysis all these parameters maintained their discriminating power (mutational status of IgV(H,)P < 0.0001; soluble CD26, P = 0.02) their combined effect on clinical outcome was assessed. When three groups were considered: (1) Low-risk group (n = 31), patients with concordant IgVH(mut) and low level of soluble CD26; (2) intermediate risk group (n = 26), patients with discordant pattern; (3) high-risk group (n = 12), patients with concordant IgVH(unmut) and high level of soluble CD26, differences in the TFT were statistically significant, with a TFT at 5 yr of respectively 88%, 51% and 43% (P < 0.0001). Our results indicate that in early B-cell CLL biological profile including among other parameters soluble CD26 may provide a useful insight into the complex interrelationship of prognostic variables. Furthermore, CD26 along with mutational status of IgV(H) can be adequately used to predict clinical behavior of patients with low risk disease.
Collapse
Affiliation(s)
- Stefano Molica
- Medical Oncology Unit, Hematology-Oncology Department, Azienda Ospedaliera Pugliese-Ciaccio, Viale Pio X - 88100 Catanzaro, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Casato M, Carlesimo M, Francia A, Timarco C, Antenucci A, Bove M, Martini H, Visentini M, Fiorilli M, Conti L. Influence of inherited and acquired thrombophilic defects on the clinical manifestations of mixed cryoglobulinaemia. Rheumatology (Oxford) 2008; 47:1659-63. [DOI: 10.1093/rheumatology/ken303] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
|
25
|
Gandolfo GM, Ferri GM, Conti L, Antenucci A, Marrone R, Frasca AM, Vitelli G. [Prevalence of infections by hepatitis A, B, C and E viruses in two different socioeconomic groups of children from Santa Cruz, Bolivia]. Med Clin (Barc) 2003; 120:725-7. [PMID: 12781080 DOI: 10.1016/s0025-7753(03)73826-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND OBJECTIVES The epidemiology of hepatitis A, E, B and C was analyzed in 1,393 children living in Santa Cruz de la Sierra, Bolivia. They were distributed in two groups according to the social condition. MATERIALS AND METHOD 1,393 children were selected from two different schools: one attended by children belonging to a high social class of the town (group A), and the other school attended by children belonging to the poorest social class (group B). Blood samples were drawn by a team of physicians from Rome University La Sapienza. Serum antibodies against hepatitis A, B, C and E virus, and the hepatitis B surface antigen were evaluated by immunometric methods. The significance was evaluated using the *2 test. RESULTS Antibodies against hepatitis A virus were detected in 82% of examined children, with a significant difference between the two groups (56.3% vs 94.8%). The incidence of anti-HBc antibodies increased with age, so the infection is acquired prevalently in adolescence with a significant difference between both groups (1.1% vs 3.8%). The same phenomenon was observed with anti-HCV antibodies (4.7% positivity only in group B). Serum antibodies against hepatitis E virus were observed in 1.7% cases. CONCLUSIONS In Bolivia, as in other developing countries, viral hepatitis represents a serious burden for public health. Spreading of viral hepatitis can be controlled upon improving hygienic conditions and customs. Moreover, a vaccination plan against hepatitis A and B virus is necessary for the population living in endemic areas.
Collapse
Affiliation(s)
- Giuseppe M Gandolfo
- Department of Experimental Medicine and Pathology. Rome University La Sapienza. Rome. Italy.
| | | | | | | | | | | | | |
Collapse
|
26
|
Gandolfo GM, Ferri GM, Conti L, Antenucci A, Marrone R, Frasca AM, Vitelli G. Prevalencia de las infecciones de los virus A, B, C y E de la hepatitis en dos grupos de niños de nivel socioeconómico distinto de Santa Cruz, Bolivia. Med Clin (Barc) 2003. [DOI: 10.1157/13048058] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
27
|
Cianciulli AM, Bovani R, Leonardo C, Iori F, Coletta AM, Marzano R, Antenucci A, Gandolfo GM, Laurenti C. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH: prognostic implications. Eur J Histochem 2001; 45:65-71. [PMID: 11411867 DOI: 10.4081/1615] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
We evaluated the genetic changes in bladder cancer biopsy by fluorescence in situ hybridization (FISH) and related them to stage and grade of the tumor, ploidy (FCM) and clinical outcome, to determine a simple method to identify tumors with a poorer prognosis. Using FISH the numerical aberrations of chromosomes 1, 7, 9, 17 in tumor's imprints of 70 patients with transitional cell cancer (TCC) were determined. First of all, the data demonstrated that the sensitivity of FISH in detecting quantitative DNA aberrations exceeds FCM's sensitivity. The frequency of chromosome 1 and 9 aberrations did not show significant differences in diploid and aneuploid tumors in different stage and grade. On the contrary, the chromosome 7 and 17 aneusomy showed greater differences between pT1 and pT2-3 tumors (p<0.032 and p<0.0006, respectively) than between stage pTa and pT1. In our investigation, an increasing number of aberrations was observed in all chromosomes examined in tumors of patients who afterwards underwent cystectomy and/or had recurrent tumors. These results suggest that chromosome 7 and 17 aneusomy could be predictive of adverse outcome in a subgroup of patients with superficial tumors at presentation.
Collapse
Affiliation(s)
- A M Cianciulli
- Clinical Pathology Service, National Cancer Institute, Rome.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Cianciulli AM, Bovani R, Leonardo F, Antenucci A, Gandolfo GM, Giannarelli D, Leonardo C, Iori F, Laurenti C. Interphase cytogenetics of bladder cancer progression: relationship between aneusomy, DNA ploidy pattern, histopathology, and clinical outcome. Int J Clin Lab Res 2001; 30:5-11. [PMID: 10984125 DOI: 10.1007/s005990070026] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
In the present study, different stages of transitional cell carcinoma of the bladder were analyzed by fluorescent in situ hybridization, using probes specific for pericentromeric classical satellite. Seventy primary tumors were evaluated for chromosomes 1, 7, 9, 17, and ploidy by flow cytometry. The results were correlated, after a mean follow-up period, with ploidy, histopathological characteristics, recurrence, and progression. Firstly, our data demonstrated that the sensitivity of fluorescence in situ hybridization in detecting quantitative DNA aberrations exceeds that of flow cytometry. The frequency of chromosome 1 and 9 aberrations was not significantly different in diploid and aneuploid tumors of different stage and grade. In contrast, the chromosome 7 and 17 aneusomy showed greater differences between pT1 and pT2-3 tumors (P<0.032 and P<0.0006, respectively) than between stage pTa and pT1. An increasing number of aberrations was observed in all chromosomes examined from tumors of patients that afterwards underwent cystectomy and/or had recurrent tumors. This study indicates that fluorescence in situ hybridization could be used to detect genetic changes relevant to patient outcome. These genetic changes could identify patients at high risk of recurrence and possible progression.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Aneuploidy
- Carcinoma, Transitional Cell/genetics
- Carcinoma, Transitional Cell/pathology
- Carcinoma, Transitional Cell/surgery
- Chromosome Aberrations
- Chromosomes, Human/ultrastructure
- Chromosomes, Human, Pair 17/ultrastructure
- Chromosomes, Human, Pair 7/ultrastructure
- Cystectomy
- DNA, Neoplasm/genetics
- Disease Progression
- Female
- Humans
- In Situ Hybridization, Fluorescence
- Male
- Middle Aged
- Neoplasm Recurrence, Local
- Neoplasm Staging
- Prospective Studies
- Treatment Outcome
- Urinary Bladder Neoplasms/genetics
- Urinary Bladder Neoplasms/pathology
- Urinary Bladder Neoplasms/surgery
Collapse
Affiliation(s)
- A M Cianciulli
- Department of Clinical Pathology, Regina Elena Cancer Institute, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Mariani L, Conti L, Antenucci A, Vercillo M, Atlante M, Gandolfo GM. Predictive value of cell kinetics in endometrial adenocarcinoma. Anticancer Res 2000; 20:3569-74. [PMID: 11131664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Flow cytometric DNA content and proliferative kinetic markers, S-phase fraction (SPF) and thymidine labeling index (TLI), were evaluated in 68 patients with endometrial carcinoma. A high rate of aneuploid tumors was detected (48.4%); median values of SPF and TLI were 6.4 and 6.2, respectively. No significant relationship emerged between ploidy status and proliferative markers in respect to clinical and pathological variables. Aneuploid tumors had a higher recurrence rate than diploid tumors (21.8% vs 9.6%), but the difference was not statistically significant. According to the median value of both kinetic markers, the study population was divided into low and high-risk, where DFS was 100% and 71.4%, respectively (p = 0.05). Furthermore, high-TLI tumors (> 6.2) had a significantly worse DFS (75.4%) than low-TLI (100%) only among patients assigned to Stage I of the disease, regardless of other pathological variables. At multivariate analysis myometrial invasion resulted as an independent and significant factor. Flow cytometric ploidy analysis was useless as a predictive biological parameter and did not add any further prognostic information to the pathologic variables. SPF and TLI values could indicate a subset of women with unexpected poor outcome in a group of patients generally considered at low-risk, i.e. Stage I. If further investigation confirms these data, it could prove useful for therapeutic planning in endometrial cancer patients. At the present time, pathological and clinical factors are still the most reliable predictive parameters.
Collapse
Affiliation(s)
- L Mariani
- Department of Gynecologic Oncology, Regina Elena National Cancer Institute of Rome, Viale Regina Elena, 291, 00162, Rome, Italy
| | | | | | | | | | | |
Collapse
|
30
|
Mazzucconi MG, Piola P, Arista MC, Bizzoni L, Antenucci A, Conti L. Modifications of lymphocyte subsets in autoimmune thrombocytopenic purpura patients submitted to splenectomy. Haematologica 2000; 85:776-7. [PMID: 10897141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
|
31
|
Di Pietrantonio G, Caputo LD, Profenna LM, Cardano F, Camboni C, Antenucci A, Cau C, Massimiani F, Righetti R. [Primary dilated cardiomyopathy]. Minerva Cardioangiol 1998; 46:195-210. [PMID: 9882963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Recent advances in etiopathogenesis and natural history of idiopathic dilated cardiomyopathy are presented. The clinical and instrumental diagnosis and therapy are also reported.
Collapse
Affiliation(s)
- G Di Pietrantonio
- III Divisione Medica Mazzoni, Azienda Ospedaliera Complesso Ospedaliero, San Giovanni Addolorata Roma
| | | | | | | | | | | | | | | | | |
Collapse
|